Biblio
Export 1092 results:
Author Title Type [ Year
Filters: First Letter Of Keyword is C [Clear All Filters]
“Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.”, Neurology, vol. 74, no. 3, pp. 201-9, 2010.
, “Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.”, Nature, vol. 467, no. 7311, pp. 95-8, 2010.
, “Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.”, PLoS One, vol. 5, no. 11, p. e13950, 2010.
, “Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.”, PLoS One, vol. 5, no. 11, p. e13950, 2010.
, “National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline.”, Ann Intern Med, vol. 153, no. 3, pp. 176-81, 2010.
, “Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy.”, J Alzheimers Dis, vol. 19, no. 1, pp. 355-61, 2010.
, “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 270-9, 2011.
, “Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons.”, Cell, vol. 146, no. 3, pp. 359-71, 2011.
, “Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons.”, Cell, vol. 146, no. 3, pp. 359-71, 2011.
, “Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.”, Lancet Neurol, vol. 10, no. 2, pp. 187-98, 2011.
, “Neuronal activity regulates the regional vulnerability to amyloid-β deposition.”, Nat Neurosci, vol. 14, no. 6, pp. 750-6, 2011.
, “Neuronal basis of age-related working memory decline.”, Nature, vol. 476, no. 7359, pp. 210-3, 2011.
, “Neuronal basis of age-related working memory decline.”, Nature, vol. 476, no. 7359, pp. 210-3, 2011.
, “Neuronal basis of age-related working memory decline.”, Nature, vol. 476, no. 7359, pp. 210-3, 2011.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
, “Report of the task force on designing clinical trials in early (predementia) AD.”, Neurology, vol. 76, no. 3, pp. 280-6, 2011.
,